Investors purchased shares of Amsurg Corp. (NASDAQ:AMSG) on weakness during trading hours on Monday. $25.91 million flowed into the stock on the tick-up and $11.80 million flowed out of the stock on the tick-down, for a money net flow of $14.11 million into the stock. Of all stocks tracked, Amsurg Corp. had the 18th highest net in-flow for the day. Amsurg Corp. traded down ($0.69) for the day and closed at $63.94

A number of analysts have recently weighed in on the stock. Mizuho upped their target price on shares of Amsurg Corp. from $84.00 to $90.00 and gave the stock a “buy” rating in a research report on Wednesday, May 4th. Jefferies Group reaffirmed a “buy” rating and issued a $96.00 target price on shares of Amsurg Corp. in a research report on Thursday, May 5th. Robert W. Baird reaffirmed a “buy” rating on shares of Amsurg Corp. in a research report on Monday, May 16th. Barclays PLC assumed coverage on shares of Amsurg Corp. in a research report on Wednesday, June 1st. They issued an “equal weight” rating and a $85.00 target price on the stock. Finally, Wells Fargo & Co. assumed coverage on shares of Amsurg Corp. in a research report on Tuesday, June 14th. They issued a “market perform” rating on the stock. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Amsurg Corp. has an average rating of “Buy” and a consensus price target of $93.91.

The stock’s 50-day moving average is $73.09 and its 200-day moving average is $74.19. The company has a market cap of $3.44 billion and a price-to-earnings ratio of 18.97.

Amsurg Corp. (NASDAQ:AMSG) last posted its earnings results on Tuesday, August 2nd. The company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.02. The company earned $758.50 million during the quarter, compared to analysts’ expectations of $769.88 million. During the same quarter last year, the firm earned $0.97 EPS. Amsurg Corp.’s revenue for the quarter was up 21.5% on a year-over-year basis. On average, equities analysts forecast that Amsurg Corp. will post $4.33 earnings per share for the current fiscal year.

Several large investors have modified their holdings of the company. Dimensional Fund Advisors LP raised its stake in shares of Amsurg Corp. by 3.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,994,029 shares of the company’s stock worth $227,552,000 after buying an additional 92,088 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Amsurg Corp. by 1,872.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 194,790 shares of the company’s stock worth $14,804,000 after buying an additional 184,912 shares during the last quarter. Morgan Stanley raised its stake in shares of Amsurg Corp. by 115.7% in the fourth quarter. Morgan Stanley now owns 182,105 shares of the company’s stock worth $13,840,000 after buying an additional 97,682 shares during the last quarter. Redwood Investments LLC raised its stake in shares of Amsurg Corp. by 20.3% in the fourth quarter. Redwood Investments LLC now owns 28,011 shares of the company’s stock worth $2,129,000 after buying an additional 4,732 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of Amsurg Corp. by 30.5% in the fourth quarter. US Bancorp DE now owns 23,339 shares of the company’s stock worth $1,774,000 after buying an additional 5,461 shares during the last quarter.

AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.